Podchaser Logo
Home
142 - Debio 1347 for FGFR gene alteration tumors; daratumumab for newly diagnosed MM; new combo for OAB; FDA warns e-liquid companies; 'Short-term' EpiPen shortage

142 - Debio 1347 for FGFR gene alteration tumors; daratumumab for newly diagnosed MM; new combo for OAB; FDA warns e-liquid companies; 'Short-term' EpiPen shortage

Released Friday, 11th May 2018
Good episode? Give it some love!
142 - Debio 1347 for FGFR gene alteration tumors; daratumumab for newly diagnosed MM; new combo for OAB; FDA warns e-liquid companies; 'Short-term' EpiPen shortage

142 - Debio 1347 for FGFR gene alteration tumors; daratumumab for newly diagnosed MM; new combo for OAB; FDA warns e-liquid companies; 'Short-term' EpiPen shortage

142 - Debio 1347 for FGFR gene alteration tumors; daratumumab for newly diagnosed MM; new combo for OAB; FDA warns e-liquid companies; 'Short-term' EpiPen shortage

142 - Debio 1347 for FGFR gene alteration tumors; daratumumab for newly diagnosed MM; new combo for OAB; FDA warns e-liquid companies; 'Short-term' EpiPen shortage

Friday, 11th May 2018
Good episode? Give it some love!
Rate Episode

May 11, 2018

Please subscribe, rate and review if you like this podcast. Thank you! The podcast website is http://newfdaapprovals.com

0:46 FDA grants Fast Track Designation to Debiopharm International's Debio 1347 for the treatment of patients with unresectable or metastatic tumors with a specific FGFR gene alteration https://www.prnewswire.com/news-releases/fda-grants-fast-track-designation-to-debiopharm-internationals-debio-1347-for-the-treatment-of-patients-with-unresectable-or-metastatic-tumors-with-a-specific-fgfr-gene-alteration-682042861.html 

2:17 Janssen announces DARZALEX® (daratumumab) U.S. FDA approval for newly diagnosed patients with multiple myeloma who are transplant ineligible https://www.prnewswire.com/news-releases/janssen-announces-darzalex-daratumumab-us-fda-approval-for-newly-diagnosed-patients-with-multiple-myeloma-who-are-transplant-ineligible-300644142.html 

5:05 FDA approves supplemental New Drug Application for Myrbetriq® (mirabegron) for use in combination with solifenacin succinate for the treatment of overactive bladder symptoms https://www.prnewswire.com/news-releases/fda-approves-supplemental-new-drug-application-for-myrbetriq-mirabegron-for-use-in-combination-with-solifenacin-succinate-for-the-treatment-of-overactive-bladder-symptoms-300644079.html

6:26 FDA warns more companies to stop misleading kids with e-liquids that resemble kid-friendly foods as part of Youth Tobacco Prevention Plan https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm607327.htm

8:14 'Short-term' EpiPen shortage, anticipates FDA https://www.cnn.com/2018/05/09/health/epipen-fda-drug-shortages-list-bn/index.html

Brought to you by Nascent Medical. For assistance with medical writing, please email [email protected].

Music credit: freemusicarchive.org/music/MindsEye/Yellow_Taxi/

Show More
Rate

Join Podchaser to...

  • Rate podcasts and episodes
  • Follow podcasts and creators
  • Create podcast and episode lists
  • & much more

Episode Tags

Do you host or manage this podcast?
Claim and edit this page to your liking.
,

Unlock more with Podchaser Pro

  • Audience Insights
  • Contact Information
  • Demographics
  • Charts
  • Sponsor History
  • and More!
Pro Features